CSL partners with AWS on AI for drug research and development
CSL has partnered with Amazon Web Services (AWS) to integrate artificial intelligence (AI) and cloud computing into its drug research and clinical development operations. The collaboration aims to help CSL scientists analyze data, identify potential drug targets sooner, and evaluate opportunities more quickly. By integrating laboratory experiments with computational research, the partnership will also streamline the flow of experimental results into research models and decision-making processes.
In clinical development, AWS technology will be used to decrease manual work in protocol writing, clinical data management, and regulatory filings. Throughout these processes, CSL will maintain data governance, traceability, and inspection readiness. This partnership was announced on Tuesday and was reported by Investing.com, with the article partially generated using AI and reviewed by an editor.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
